Health Archive » November, 2010

Health - November, 2010

202 articles

• Doctor Indicted Over False Fen-Phen Injury Claims
• Quest, Lab Techs Settle FLSA Suit For $2M
• Justices Wrangle With Standard In Cigna Pension Case
• Novartis Wins OK On $175M Deal To End Bias Action
• 3rd Circ. Revives Suit Against UPMC, Highmark
• AIDS Nonprofit Says BMS Overcharged For Drugs
• J&J Units Target Impax Over Generic Concerta
• AMAG Updates Feraheme Label To Include Safety Risks
• Allergan, AMD, Bosch Face False Marking Suits
• The FTC's Aggression Affirmed
• Alzheimer's Group Hits UPenn, Avid With Patent Suit
• J&J Must Pay Basilea $130M Over License: Dutch Court
• Cardinal Health Buys Chinese Drug Importer For $470M
• New EU Rule Eases Biosimilar Development
• Syntrix Slaps Illumina With Biotech Patent Suit
• Coventry Wins Partial Toss Of Copay Class Action
• Federal Circ. Fleshes Out Prosecution Laches
• Nev. High Court Affirms $58M Award Against Wyeth
• 10 Tips For Avoiding GINA Violations
• Novartis Hit With $1M Ruling In Aredia, Zometa Suit
• NZ Air Ambulance Cos. Settle Price-Fixing Claims
• J&J Recalls 9M Tylenol Meds Over Missing Alcohol Label
• Judge Delays Recusal Ruling For Siegelman, Scrushy
• FDA Crime Head To Depart Amid Misconduct Claims
• Sonova Recalls Cochlear Implants Made By US Unit
• Genzyme, Daiichi Sankyo Fight More Welchol ANDAs
• Judge Won't Rehear Dismissal Bid In Wyeth Pristiq Suit
• McKesson Wins $44M In Iranian Dairy Stake Suit
• 7th Circ. Pins Down Atty Fee Awards In Lanham Case
• J&J Pulls Children's Benadryl, Motrin Off Shelves
• Philly Judge Nixes GSK Paxil Birth Defect Suit
• Pharma Struggles To Escape FCPA Net
• Ohio Group's Health-Law Suit Survives Dismissal Bid
• Implant Maker Seeks To Subpoena Dickstein In IP Spat
• Wyeth Appeals Retaliation Trial Order To High Court
• P&G Asks To Fight Align Suit On Home Turf
• The Content Marketing Revolution
• Senate Commerce Chief Decries Mini-Med Exemption
• Amgen Loses Bid To Wrap Up Teva Patent Fight
• FCA Settlements Top $3B In FY2010
• Chubb Off Hook For IP Suit Over Nutrition Co. Ad
• Bracing For Cigna V. Amara
• Life Tech Sues GenMark Over DNA Test Patent
• HHS Releases Medical-Loss Ratio Regulation
• Avandia Plaintiffs Must Comply With Lone Pine Order: Judge
• Merck Picks Up Another Win In Fosamax Bellwether
• Darvon Maker Pulls Painkiller From US Market
• W.Va. High Court Nixes $4.5M Verdict Against J&J Unit
• Bristol-Myers Hit With False Marking Suit Over 3 Drugs
• CIBC Continues To Dog Attys In Chem Rx Ch. 11
• Sens. Pitch Plan To Let States Opt Out Of Health Reform
• Merck Unit Sues TriGen Over Folic Acid Patents
• Medicare Fraudster Gets 5 Years, $7.9M Restitution
• Class Attys Score $38M Fee In Novartis Sex Bias Suit
• The 21st-Century Law Firm
• EU Drug Agency OKs Rule On Biosimilar Antibodies
• Vioxx Plaintiffs Take $5B Deal Woes To High Court
• King Investors Fail To Speed Suit Over $3.6B Pfizer Sale
• Jones Day Lures Biotech IP Partners From McDermott
• Calif. Nurses Lose Wage Class Action Appeal
• Attorney Suspended Over Conduct In Black Lung Case
• Bristol-Myers Sales Rep Sues For Overtime Pay
• Ropes Gray Reps Genzyme In $265M Diagnostics Sale
• France Says Diabetes Drug May Have Led To 500 Deaths
• Smith & Nephew Loses 2nd Bid To Kill FCA Dispute
• Siga Says Survey Will Bolster Bid For $2.8B Contract
• Wachtell Reps Cardinal Health In $1.3B Kinray Buy
• Upsher-Smith Faces False Marking Suit Over Diet Drug
• 2nd Circ. Remands State Claims In Pfizer Firing Suit
• Safe Life Settles Fight Over 3M Respirator Patents
• The Challenges Of FDA's Nascent Biosimilars Regime
• Ameritox To Pay $16M To Resolve Medicaid FCA Suit
• Rituxan Wrongful Death Suit Stays In Federal Court
• Greenberg Adds Veteran Senate Atty To Health Group
• Cancer Patients Lose Discovery Battle With Insurer
• Mobile Medical Loses Fight For Veterans Hospital Job
• $3M Bail Set For Doctor Accused Of Tipping Off Fund
• Stanford Appeal Reignites IP Custody Battle
• Ex-Baseball Player Gets 9 Years For Medicare Fraud
• FDA Accused Of Contempt In Plan B Availability Case
• Settlement Funds Established In Avandia MDL
• Stryker Can't Nix USPTO Ruling In Bone Screw IP Row
• 3 Things Accountable Care Organizations Can Do Now
• Lilly Chemotherapy Drug Patent Valid, Judge Rules
• Contractor, US Settle Over Clinic Construction Delays
• Insurer On Hook For Defense In BestComp E&O Suit
• Judge Clears Path For Generic Dr. Reddy's Asthma Drug
• CIBC Fights Fox Rothschild Fees In Chem Rx Ch. 11
• HHS Eases Restrictions On Grandfathered Plans
• Healthfirst Hands Over $7.7M In Marketing Rep OT Suit
• FDA Seeks To Improve Safety Of Heart Defibrillators
• State Lawmakers Back Health Care Reform
• Universal Health Agrees To Divest For $3.1B PSI Deal
• Otsuka Triumphs In Abilify Patent Litigation
• Pay-For-Delay Is Smart And Legal, Drugmakers Argue
• Hospira Sues Caraco To Block Generic Precedex
• SG To Participate In Cigna High Court Pension Fight
• Flonase Purchasers Win Class Cert. In Suit Against GSK
• M&A Risks To Your 'Grandfathered' Health Plan
• Medicare Fraud Units Will Scrutinize Health Care Cos.
• Foxhollow Loses Bid To Toss Merger Breach Suit
• Doctor Preps Bail Package In Hedge Fund Tip-Off Case
• Utah Slaps GSK With Medicaid Fraud Suit Over Avandia
• Ecolab To Snatch Up OR Solutions For $260M
• Economists Back Obama On Health Care Reform
• BASF Dodges Claims From Vitamin Cartel Victims
• Smith & Nephew Asks Court To Rethink FCA Ruling
• Brazil Probes Alleged Ambulance Bid-Rigging Scheme
• US Reversal Frames Issues In Myriad's Appeal
• FDA Releases Raw Heparin Shipments To Amphastar
• Changes In Doctor Payments Under EHR Incentive
• Convicted Pharma Fraudster Seeks Post-Trial Acquittal
• Teva, Others Settle With Counties In Medicaid MDL
• Hawaii Sues McKesson For Allegedly Inflating AWPs
• AstraZeneca Hits Watson With Crestor Patent Suit
• Pfizer Fights Whistleblower Retaliation Suit In 2nd Circ.
• Fed. Circ. Revives Merck Suit Over Temodar Patent
• Cobalt's Generic Boniva Barred In Roche IP Spat
• Mylan Reaches $2.6M Deal In Mass. Medicaid Case
• GOP Senate Leader Backs Suit Over Health Care Reform
• Fed. Circ. Nixes Abraxis Win In Naropin Patent Row
• Feds Hit Back At Stryker Biotech's Dismissal Bids
• Fla. Man Says Philip Morris Should Fund Lung Tests
• Prevention Beats Cure For Medicare Enrollment
• DC Circ. Upholds Exclusivity For ADHD Drug Vyvanse
• Md. Hospital To Pay $22M To Settle Kickback Claims
• Abbott, Others Argue For New Inequitable Conduct Rule
• Omnicare Investors Drop High Court Appeal
• Ex-GSK Atty Indicted For Obstructing Federal Probe
• Class Action Alleges Dexatrim Contains Carcinogen
• FDA Warns Claris Over Contaminated Drugs
• FDA Got Too Close To Drug Firms: GAO
• House Leaders To Probe FDA's Puerto Rico Office
• Navy Defends Decision To Nix $15M Drug Test Deal
• FDA Blames GE, Toshiba Radiation Problems On Misuse
• Wyeth Effexor Patent Valid, Infringed: Australian Judge
• Novo Nordisk, Actavis End PrandiMet Patent Spat
• DOJ Ends Reagents Antitrust Probe Into Immucor
• Navigating CMS' New Self-Referral Disclosure Protocol
• AAI Urges FTC To Reconsider CVS Caremark Merger
• Edwards Lifesciences Subpoenaed Over Heart Monitor
• Centocor Loses Bid To Dismiss Remicade Suit
• High Court Considers Tax Status Of Medical Residents
• Tulsa Medical Center Can't Escape Medicaid Suit
• Kaiser Health Inks $2.9M Settlement With IT Staff
• Judge Reinstates Opt-Ins In Pa. Hospital FLSA Action
• Inequitable Conduct Doctrine Takes Stage In Fed. Circ.
• Siga Appeals $2.8B Drug-Contract Disqualification
• Whistleblowers Seek To Revive Suit Against Medco
• Q&A With Dinsmore & Shohl's James Zeszutek
• High Court Won't Hear Calif. Group's Health Law Fight
• Weil Gotshal Advises Lilly In $800M Avid Deal
• 10 Appellate Tips From A Former Chief Justice
• Five Nabbed In Texas Over $10M Medicare Scheme
• Arnzen Molloy Can Stay On Harassment Indemnity Suit
• Ex-Bristol Myers Worker Pleads Guilty To IP Theft
• US, States Feud Over Health Care Reform
• Dendreon Inks $17M Deal In Shareholder Action
• FDA Falls Short On Medical Device Monitoring: Report
• Akzo, AstraZeneca Face 'Dead Peasant' Policy Suit
• State Farm Dodges Class Action Over Medicare
• Pharmacy's Provigil Action To Remain In Federal Court
• Astellas Targets Glenmark Over Eczema Drug
• Nanoparticles: A New Mass Tort Frontier
• Smith & Nephew Fails To Shake Whistleblower Suit
• Class Can't Kill Plaintiffs Atty's AWP Ban Appeal
• KV Securities Plaintiffs Fight Denial Of Bid To Amend
• The Government Stance On Generic Preemption
• Alleged $42M Construction Kickbacker Seeks Severance
• Valeant Settles Biovail Frivolous Suit Claims For $10M
• Judge Squashes Hostess Trans Fat Labeling Suit
• Allergan's Bid For New Trial Rejected In Zymar Case
• MDL Judge Wants More Info On Zicam Settlement
• Genzyme Sues Lupin Over Generic Welchol
• Election Leaves Fate Of Patent Reform Up In The Air
• Nationwide Settles Coverage Suit Over Corpse Sales
• Watson Reaches Deal With J&J For Concerta Generic
• 5th Circ. Revives Cardinal Health Qui Tam Suit
• Health Care Unions Actively Using New Tactics
• Fosamax Judge Restricts Bellwether Trial Evidence
• Ariz., Okla. Voters Reject Obama's Health Care Mandate
• Thermo Fisher Hit With Patent Suit Over Lab Device
• DOJ's Policy Shift Could Change Future Of DNA IP
• Chem Rx's $70M Sale To PharMerica Gets Green Light
• FDA Starts On Path To Approving Biosimilars
• French Doctor Busted For Allegedly Selling Inside Tips
• Mylan Drops Appeal In Generic Paxil Contract Fight
• CareFusion Antitrust Claims Nixed In Medtronic Suit
• Fed. Circ. Denies Lilly En Banc Review In Gemzar Feud
• FDA Issues Class I Recall Of Medtronic's Octopus Nuvo
• Fed. Circ. Upholds Injunction On Generic Pulmicort
• Skadden Reps McKesson In $2B US Oncology Deal
• Cancer Patients Fight Insurer's Bid To Block Discovery
• Supreme Court Disbars Former Fen-Phen Torts Atty
• Pfizer Recalls 38,000 More Bottles Of Lipitor
• Army Properly Rejected Medfinity X-Ray Bid: GAO
• Blue Cross Michigan Hit With 'Most Favored' Action
• Fresenius Goes After Lupin Over PhosLo ANDA
• DOJ Urges Compromise In Gene Patent Appeal Brief
• GAO Sustains Bid Protest Over VA Hospital Contract
• High Court To Weigh Rights In Gov't-Funded Inventions
• Increasing Scrutiny Of Gov't Contingent Fee Deals